SAT0157 MYCOBACTERIUM TUBERCULOSIS SPECIFIC RESPONSES FROM CD8+ AND CD4+ T CELLS IN PATIENTS WITH LATENT AND ACTIVE FORM OF TUBERCULOSIS
Background: Testing the presence of latent or active tuberculosis using IGRA tests is necessary part of the diagnostic screening at risk individuals. QuantiFERON-TB Gold Plus (QFT-Plus) is a test for cell-mediated immune (CMI) responses to peptide antigens that simulate mycobacterial proteins. Peptide antigens in TB1 tube elicit CMI responses from CD4+ T-helper lymphocytes, in TB2 tube from CD8+ T-cytotoxic lymphocytes. Test is based on the ability of effector T lymphocytes to produce the cytokine interferon gamma (IFN-γ). Objectives: To compare and evaluate levels of IFN-γ produced by CD4+ and CD8+ cells in TB1 and TB2 tubes. Methods: It was studied 33 subjects with latent form of tuberculosis (LTBI) and 33 subjects with active TB. QFT-Plus was used to detect in vitro responses to peptide antigens associated with Mycobacterium tuberculosis infection (ELISA, QIAGEN). Results were obtained by calculation of INF-γ levels in Mitogen, TB antigen (TB1, TB2) and Negative control tubes using QFT analysis software. Results: QFT-Plus positive results were observed in both groups of people. Increased levels of IFN-γ produced by CD4+ cells (TB1) has been detected in 21 subjects with LTBI (63,64%) and in all 33 subjects with active TB (100,0%). Increased levels of IFN-γ produced by CD8+ cells (TB2) has been detected in 27 people with LTBI (81,82%) and in all 33 people with active TB (100,0%). Joint increase levels of IFN-γ in the tubes TB1 and TB2 was observed in 16 individuals with LTBI (48,48%) and in all 33 individuals with active TB (100,0%). In the group of patients with a negative QFT-Plus it was not observed increased levels of IFN in tubes TB1 and TB2. Conclusions: Our findings confirm specific CD4+ and CD8+ T cell response to mycobacterial protein antigens in individuals with LTBI and also in active TB subjects, in which INF-γ was frequently found. The immunological response represented by CD4+ and CD8+ T cells was not detected in subjects with QFT-Plus negative. Background: The strategy for the choice of the second biologic agent after the failure of the first TNF inhibitor (TNFi) is still an unclear aspect in the treatment of both rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Switching between structurally different TNFis (from etanercept [ETN] to monoclonal antibody [mAb] or vice versa) has been proposed as a more effective procedure than switching among different mAbs, but to date no study has been specifically focused on exploring this topic. Objectives: To evaluate the comparative 2-year retention rate and the 12-month efficacy of adalimumab (ADA) as second biologic agent in etanercept (ETN) non-responder RA and PsA patients in a multicentre retrospective study. Methods: All RA and PsA patients from 11 Italian Rheumatology Units treated with ADA after a first-course ETN failure and with at least 12-month follow-up were retrospectively collected in a multicentre registry. Data analysis was limited to the period from January 2002 to May 2016. Two-year ADA retention rate was calculated by Kaplan-Meier method. 12-month ADA response was defined as achievement of disease activity score 28 calculated by using erythrosedimentation (DAS28-ESR) <2.6 (remission) or >2.6 and <3.2 (low disease activity, LDA 
